Best Supplements for Reduced Hospitalization Duration
Ranked by research evidence. Compare 7 supplements across 11 papers from the biomedical literature, with effect direction, evidence strength, and dose range for each.
Top picks by evidence
- Moderate evidence3 studies
Across 3 studies, all reported beneficial effects on reduced hospitalization duration. Effect sizes were mixed (small to large). The evidence is derived from children with acute gastroenteritis (2 studies) and preterm neonates (1 study); doses were not consistently reported.
- Low evidence3 studies
Across 3 studies, all reported beneficial effects of Lactobacillus reuteri UALre-16 on reducing hospitalization duration, with effect sizes ranging from small to large. Two of 3 studies reached statistical significance. Evidence is available for children with acute gastroenteritis (small effect: MD -0.54 days) and preterm neonates (large effect: -10.77 days), but no consistent dose or form was reported.
Top combinations for Reduced Hospitalization Duration
most supplement research is combination research- Low evidence
Across 3 papers studying the combination of Lactobacillus reuteri MAK02L14R and Lactobacillus reuteri UALre-16 for reduced hospitalization duration, all reported beneficial effects, with 2 of 3 finding statistically significant reductions. Effect sizes were mixed, ranging from small reductions (−0.54 days) in children with acute gastroenteritis to large reductions (−10.77 days) in preterm neonates. These results are similar to the solo syntheses for both strains individually, but the combination evidence is limited by the fact that the studies labeled the intervention generically as 'L. reuteri DSM 17938', making it impossible to attribute effects to the specific combination of MAK02L14R and UALre-16 strains.
- ModerateLactobacillus reuteri MAK02L14RAcross 3 studies, all reported beneficial effects on reduced hospitalization duration. Effect sizes were mixed (small to large). The evidence is derived from children with acute gastroenteritis (2 studies) and preterm neonates (1 study); doses were not consistently reported.3 beneficial3 studies
- LowLactobacillus reuteri UALre-16Across 3 studies, all reported beneficial effects of Lactobacillus reuteri UALre-16 on reducing hospitalization duration, with effect sizes ranging from small to large. Two of 3 studies reached statistical significance. Evidence is available for children with acute gastroenteritis (small effect: MD -0.54 days) and preterm neonates (large effect: -10.77 days), but no consistent dose or form was reported.3 beneficial3 studies